Anti-HER2-targeted therapies: effects on human <i>in vitro</i> blood-brain barrier models.

ABSTRACT: Metastatic breast cancer is associated with very poor overall survival and a reduced quality of life. HER2-positive breast cancer forms brain metastases at the late stages. Established therapies such as trastuzumab, pertuzumab, trastuzumab/pertuzumab, lapatinib and tucatinib are widely used and are selectively toxic to HER2-positive breast cancer cell line. However, the effects of these therapies on the properties of the blood-brain barrier (BBB) remain unclear. We investigated this using an in vitro human BBB model derived from CD34⁺ cells differentiated into brain-like endothelial cells (BLECs) and hCMEC/D3 cell line. BLECs were treated with different concentrations of trastuzumab, pertuzumab, trastuzumab/pertuzumab, lapatinib or tucatinib for 24 h and 48 h. We measured

SUBMITTER: Curtaz CJ 

PROVIDER: S-EPMC12819789 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature